Active areas of research in this field include combinations of immune checkpoint inhibitors, combination tyrosine kinase and immune checkpoint inhibitors, cancer vaccines, and glucocorticoid receptor antagonists combined with immune checkpoint inhibitor therapies. This evidence concerns the gene NR3C1 and cancer.